Molecular Partners Ag (MOLN) Operating Margin (2022 - 2025)
Molecular Partners Ag (MOLN) posted quarterly Operating Margin of 100000.0% for Q2 2025, up 102994513217.0% year-over-year from N/an in Q2 2024, and up 99.99% quarter-over-quarter from 1030045132.17% in Q2 2024.
Molecular Partners Ag (MOLN) Operating Margin (2022 - 2025) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Operating Margin for 4 consecutive years, with 100000.0% the latest figure, recorded in Q2 2025.
- In Q2 2025, Operating Margin rose 102994513217.0% year-over-year to 100000.0%; the TTM figure through Jun 2025 stood at 12.99% (changed N/A YoY), while the FY2025 annual figure was 100041308.09%, up 112429869191.0% from the prior year.
- Operating Margin rose to 100000.0% in Q2 2025 per MOLN's latest filing, from 1030045132.17% in the prior quarter.
- Across five years, Operating Margin topped out at 1297.44% in Q2 2022 and bottomed at 1030045132.17% in Q2 2024.
- Historically, Operating Margin has averaged 257536915.49% across 4 years, with a median of 51913.61% in 2023.
- Annual changes were most pronounced in 2024 — Operating Margin sank 2000000000 bps — and 2025, when it jumped 2000000000 bps.
- Molecular Partners Ag's Operating Margin stood at 1297.44% in 2022, then tumbled by 395 bps to 3827.23% in 2023, then slumped by 26913501 bps to 1030045132.17% in 2024, then jumped by 100 bps to 100000.0% in 2025.
- Business Quant data shows MOLN's Operating Margin at 100000.0% in Q2 2025, 1030045132.17% in Q2 2024, and 3827.23% in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 19.75% |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -100,000.00% |
| Jun 30, 2024 | -1,030,045,132.17% |
| Jun 30, 2023 | -3,827.23% |
| Jun 30, 2022 | 1,297.44% |